Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model
Standard
Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model. / Gomarteli, Kaga; Fleckenstein, Jens; Kirschner, Stefanie; Bobu, Vladimir; Brockmann, Marc A; Henzler, Thomas; Meyer, Mathias; Riffel, Philipp; Schönberg, Stefan O; Veldwijk, Marlon R; Kränzlin, Bettina; Hoerner, Christian; Glatting, Gerhard; Wenz, Frederik; Herskind, Carsten; Giordano, Frank A.
in: SCI REP-UK, Jahrgang 9, Nr. 1, 29.10.2019, S. 15489.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model
AU - Gomarteli, Kaga
AU - Fleckenstein, Jens
AU - Kirschner, Stefanie
AU - Bobu, Vladimir
AU - Brockmann, Marc A
AU - Henzler, Thomas
AU - Meyer, Mathias
AU - Riffel, Philipp
AU - Schönberg, Stefan O
AU - Veldwijk, Marlon R
AU - Kränzlin, Bettina
AU - Hoerner, Christian
AU - Glatting, Gerhard
AU - Wenz, Frederik
AU - Herskind, Carsten
AU - Giordano, Frank A
PY - 2019/10/29
Y1 - 2019/10/29
N2 - A long-standing hypothesis in radiotherapy is that intensity-modulated radiotherapy (IMRT) increases the risk of second cancer due to low-dose exposure of large volumes of normal tissue. Therefore, young patients are still treated with conventional techniques rather than with modern IMRT. We challenged this hypothesis in first-of-its-kind experiments using an animal model. Cancer-prone Tp53+/C273X knockout rats received mediastinal irradiation with 3 × 5 or 3 × 8 Gy using volumetric-modulated arc therapy (VMAT, an advanced IMRT) or conventional anterior-posterior/posterior-anterior (AP/PA) beams using non-irradiated rats as controls (n = 15/group, ntotal = 90). Tumors were assigned to volumes receiving 90-107%, 50-90%, 5-50%, and <5% of the target dose and characterized by histology and loss-of-heterozygosity (LOH). Irradiated rats predominantly developed lymphomas and sarcomas in areas receiving 50-107% (n = 26) rather than 5-50% (n = 7) of the target dose. Latency was significantly shortened only after 3 × 8 Gy vs. controls (p < 0.0001). The frequency (14/28 vs. 19/29; p = 0.29) and latency (218 vs. 189 days; p = 0.17) of radiation-associated tumors were similar after VMAT vs. AP/PA. LOH was strongly associated with sarcoma but not with treatment. The results do not support the hypothesis that IMRT increases the risk of second cancer. Thus the current practice of withholding dose-sparing IMRT from young patients may need to be re-evaluated.
AB - A long-standing hypothesis in radiotherapy is that intensity-modulated radiotherapy (IMRT) increases the risk of second cancer due to low-dose exposure of large volumes of normal tissue. Therefore, young patients are still treated with conventional techniques rather than with modern IMRT. We challenged this hypothesis in first-of-its-kind experiments using an animal model. Cancer-prone Tp53+/C273X knockout rats received mediastinal irradiation with 3 × 5 or 3 × 8 Gy using volumetric-modulated arc therapy (VMAT, an advanced IMRT) or conventional anterior-posterior/posterior-anterior (AP/PA) beams using non-irradiated rats as controls (n = 15/group, ntotal = 90). Tumors were assigned to volumes receiving 90-107%, 50-90%, 5-50%, and <5% of the target dose and characterized by histology and loss-of-heterozygosity (LOH). Irradiated rats predominantly developed lymphomas and sarcomas in areas receiving 50-107% (n = 26) rather than 5-50% (n = 7) of the target dose. Latency was significantly shortened only after 3 × 8 Gy vs. controls (p < 0.0001). The frequency (14/28 vs. 19/29; p = 0.29) and latency (218 vs. 189 days; p = 0.17) of radiation-associated tumors were similar after VMAT vs. AP/PA. LOH was strongly associated with sarcoma but not with treatment. The results do not support the hypothesis that IMRT increases the risk of second cancer. Thus the current practice of withholding dose-sparing IMRT from young patients may need to be re-evaluated.
U2 - 10.1038/s41598-019-51735-3
DO - 10.1038/s41598-019-51735-3
M3 - SCORING: Journal article
C2 - 31664066
VL - 9
SP - 15489
JO - SCI REP-UK
JF - SCI REP-UK
SN - 2045-2322
IS - 1
ER -